Orchestra BioMed (Nasdaq:OBIO) announced today that it entered into a termination and right of first refusal agreement with Terumo. The agreement relates to the New Hope, Pennsylvania–based company's Virtue Sirolimus AngioInfusion Balloon (SAB). It supersedes and terminates a prior distribution agreement between the companies and grants Terumo a … [Read more...] about Orchestra BioMed, Terumo terminate drug-eluting balloon distro deal in $30M agreement
Balloons
Boston Scientific shares positive Agent drug-coated balloon findings
Boston Scientific (NYSE: BSX) today shared findings from new analyses of its Agent drug-coated balloon (DCB). Agent serves as an alternative to traditional therapies like balloon angioplasty, additional layers of stenting or radiation. The paclitaxel-coated balloon transfers a therapeutic dose of drug to the vessel wall, helping to prevent … [Read more...] about Boston Scientific shares positive Agent drug-coated balloon findings
Orchestra BioMed enrolls first patient in Sirolumus AngioInfusion balloon trial
Orchestra BioMed (Nasdaq:OBIO) today announced the first patient enrollments in a study of its Virtue Sirolimus AngioInfusion Balloon (SAB). The FDA investigational device exemption (IDE) trial compares the Virtue SAB to the Boston Scientific Agent paclitaxel-coated balloon. Agent is currently the only FDA-approved drug-coated balloon (DCB) for … [Read more...] about Orchestra BioMed enrolls first patient in Sirolumus AngioInfusion balloon trial
Multiple studies back Cordis Selution SLR drug-eluting balloon
Cordis today announced new findings from a duo of studies supporting the use of its Selution SLR drug-eluting balloon (DEB) system. Miami Lakes, Florida-based Cordis announced results from the SELUTION DeNovo and SELUTION 4ISR trials at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco. Both randomized clinical … [Read more...] about Multiple studies back Cordis Selution SLR drug-eluting balloon
Merit Medical to acquire cryoballoon tech from Pentax
Merit Medical Systems (Nasdaq:MMSI) announced an agreement to acquire the C2 CryoBalloon device from a Pentax Medical subsidiary. South Jordan, Utah-based Merit signed a definitive asset purchase agreement with Pentax of America over the C2 CryoBalloon and related technology. The companies expect the closing of the deal to occur during the fourth … [Read more...] about Merit Medical to acquire cryoballoon tech from Pentax
Medtronic launches full U.S. distribution of Neuroguard IEP carotid stent system
Medtronic today announced the full U.S. rollout of the Neuroguard IEP system, a carotid stent and embolic protection device. The launch follows a limited market release and builds on Medtronic’s exclusive U.S. distribution agreement with the device’s developer Contego Medical. Neuroguard IEP combines a nitinol stent, dilation balloon and … [Read more...] about Medtronic launches full U.S. distribution of Neuroguard IEP carotid stent system
Airiver Medical wins FDA IDE for pulmonary drug-coated balloon
Airiver Medical announced today that it received FDA investigational device exemption (IDE) for its pulmonary drug-coated balloon (DCB). The Brooklyn Park, Minnesota-based company designed its DCB to treat central airway stenosis. This FDA IDE – the company's first — allows it to begin a pivotal clinical trial of the technology. Central airway … [Read more...] about Airiver Medical wins FDA IDE for pulmonary drug-coated balloon
Boston Scientific launches head-to-head drug-coated balloon trial
Boston Scientific (NYSE:BSX) announced today that it initiated a new trial to assess its Agent DCB compared to the standard of care. The AGENT DCB STANCE trial pits the drug-coated balloon (DCB) head-to-head against percutaneous coronary intervention (PCI) treatment with drug-eluting stents (DES) and/or balloon angioplasty – in patients with de … [Read more...] about Boston Scientific launches head-to-head drug-coated balloon trial
Boston Scientific earns Medicare reimbursement for Agent drug-coated balloon
Boston Scientific (NYSE: BSX) announced today that CMS granted reimbursement for its Agent drug-coated balloon (DCB). CMS granted a new technology add-on payment (NTAP) for eligible cases using Agent. NTAP provides additional reimbursement to hospitals that use designated new medical technologies in the first few years of market introduction. … [Read more...] about Boston Scientific earns Medicare reimbursement for Agent drug-coated balloon
AngioDynamics enrolls first patient in atherectomy system study
AngioDynamics (Nasdaq:ANGO) announced today that it enrolled the first patient in a randomized study of its Auryon atherectomy system. The AMBITION BTK study looks at Auryon in combination with standard balloon angioplasty in treating infrapopliteal lesions in subjects with critical limb ischemia below the knee. It compares this therapy method to … [Read more...] about AngioDynamics enrolls first patient in atherectomy system study
